A Definitive IMRT-SIB with ConcomitantChemotherapy for Synchronous Locally AdvancedAnal Canal Cancer and Prostate Cancer

Currently, there are no specific recommendations regarding the management of the synchronous tumours due to the lack of eitherspecific guidelines or individuals’clinical experiences relative to these clinical situations. In the presence of a locally advanceddouble primary tumour and with the lymph node metastases in addition, from the radiotherapeutical point of view, it must bechallenging to manage this complicated situation that requires a more delicate treatment planning, due to higher dosesprescribed to greater volumes concomitantly with the chemotherapy. A 68-year-old Caucasian male with a synchronousintermediate-risk prostate adenocarcinoma and locally advanced anal canal carcinoma underwent IMRT-SIB with concomitantchemotherapy at our institute. Two years after the treatment, the restaging CT and MRI scan showed no evidence of the diseaseand the patient reported no significant gastrointestinal or genitourinary toxicity. Our experience is unique, since it is thefirstreport on using the IMRT-SIB technique simultaneously with chemotherapy in the management of the synchronous prostateand anal canal carcinomas. Therefore, wefind it important to provide the current literature with the results from our experiencewhich show good feasibility, efficacy, and tolerability of the definitive concomitant IMRT-SIB-chemotherapy for thesynchronous anal canal cancer and prostate cancer.